Blood online
Home About Blood Authors Subscriptions Permission Advertising Public Access contact us
 

 
Advanced
Current Issue
First Edition
Future Articles
Archives
Submit to Blood
Search
American Society of Hematology
Meeting Abstracts
Email Alerts
 Blood, 15 March 2005, Vol. 105, No. 6, pp. 2428-2435.
Prepublished online as a Blood First Edition Paper on November 9, 2004; DOI 10.1182/blood-2004-09-3458.

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
2004-09-3458v1
105/6/2428    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Saudemont, A.
Right arrow Articles by Quesnel, B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Saudemont, A.
Right arrow Articles by Quesnel, B.
Related Collections
Right arrow Immunobiology
Right arrow Neoplasia
Right arrow Immunotherapy
Right arrow Chemokines, Cytokines, and Interleukins
Right arrowRelated Article in Blood Online
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

arrow to previous article Previous Article  |  Table of Contents  |  Next Article next article arrow

IMMUNOBIOLOGY

NK cells that are activated by CXCL10 can kill dormant tumor cells that resist CTL-mediated lysis and can express B7-H1 that stimulates T cells

Aurore Saudemont, Nathalie Jouy, Dominique Hetuin, and Bruno Quesnel

From the Institut National de la Santé et de Recherche Médicale (INSERM) Unité 524, Institut de Recherche sur le Cancer de Lille, Lille, France; Institut Fédératif de Recherche 114, Lille, France; and Service des Maladies du Sang, Centre Hospitalier et Universitaire de Lille, Lille, France.

Tumor dormancy is a phenomenon where small numbers of tumor cells persist in the host for months or years. We previously showed in the DA1-3b/C3H mouse model of acute myeloid leukemia that dormant tumor cells resist cytotoxic T-lymphocyte (CTL)–mediated killing because they overexpress B7-H1. Here, we vaccinated mice with DA1-3b cells transduced with CXCL10. Vaccinated mice developed a strong systemic immunity that led to the cure of established leukemia without persistence of dormant tumor cells. In vivo depletion of natural killer (NK) cells from the mice abrogated the protective effect of the vaccine. Long-term persistent leukemic cells resist CTL-mediated lysis but were killed by NK cells from mice vaccinated with DA1-3b/CXCL10. These NK cells expressed B7-H1. Recombinant CXCL10, CXCL9, CXCL11, and CXCL12 chemokines induced expression of B7-H1 on mouse and human NK cells in vitro. Mouse and human B7-H1+ NK cells induced proliferation of T cells and production of interferon {gamma} and tumor necrosis factor {alpha} in vitro, and in vivo blocking of B7-H1 inhibited the protective effect of vaccination. Thus, CXCL10 induces antileukemic immunity, at least partially by stimulating NK cells to express B7-H1+. This antitumor effect is in contrast to the effect of B7-H1 when expressed on tumor cells because it stops cytotoxic lymphocytes from killing those tumor cells.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?

Related Article in Blood Online:

B7-H1 connection of innate and adaptive immunity against tumor dormancy
Lieping Chen
Blood 2005 105: 2242-2243. [Full Text] [PDF]



This article has been cited by other articles:


Home page
 Cancer Res.Home page
M. Pletneva, H. Fan, J.-J. Park, V. Radojcic, C. Jie, Y. Yu, C. Chan, A. Redwood, D. Pardoll, and F. Housseau
IFN-Producing Killer Dendritic Cells Are Antigen-Presenting Cells Endowed with T-Cell Cross-Priming Capacity
Cancer Res., August 15, 2009; 69(16): 6607 - 6614.
[Abstract] [Full Text] [PDF]

Home page
 JEMHome page
D.-M. Kuang, Q. Zhao, C. Peng, J. Xu, J.-P. Zhang, C. Wu, and L. Zheng
Activated monocytes in peritumoral stroma of hepatocellular carcinoma foster immune privilege and disease progression through PD-L1
J. Exp. Med., June 8, 2009; 206(6): 1327 - 1337.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
A. Saudemont, F. Garcon, H. Yadi, M. Roche-Molina, N. Kim, A. Segonds-Pichon, A. Martin-Fontecha, K. Okkenhaug, and F. Colucci
p110{gamma} and p110{delta} isoforms of phosphoinositide 3-kinase differentially regulate natural killer cell migration in health and disease
PNAS, April 7, 2009; 106(14): 5795 - 5800.
[Abstract] [Full Text] [PDF]

Home page
 J. Leukoc. Biol.Home page
A. Iannello, O. Debbeche, S. Samarani, and A. Ahmad
Antiviral NK cell responses in HIV infection: I. NK cell receptor genes as determinants of HIV resistance and progression to AIDS
J. Leukoc. Biol., July 1, 2008; 84(1): 1 - 26.
[Abstract] [Full Text] [PDF]

Home page
 JEMHome page
C. Petrovas, J. P. Casazza, J. M. Brenchley, D. A. Price, E. Gostick, W. C. Adams, M. L. Precopio, T. Schacker, M. Roederer, D. C. Douek, et al.
PD-1 is a regulator of virus-specific CD8+ T cell survival in HIV infection
J. Exp. Med., September 5, 2006; (2006) jem.20061496.
[Abstract] [Full Text] [PDF]


click for free articles
home about blood authors subscriptions permissions advertising public access contact us
  Copyright © 2005 by American Society of Hematology         Online ISSN: 1528-0020